14 results about "Asthma model" patented technology

The invention discloses an application of isothunberine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating asthma diseases. It is found that in an OVA-induced mouse asthma model, the isothunberine significantly reduces airway resistance excited by acetylcholine, improves inflammatory cell infiltration and airway mucus high secretion of asthma model mouse lung tissue, reduces the levels of lgE and OVA-lgE in serum and related inflammatory factors in alveolar lavage fluid, and has the effect of preventing and treating asthma. Therefore, the effect of treating asthma is achieved. Therefore, the isothunberine has the potential of preventing or treating the asthma, provides a new treatment mode for the treatment of the asthma, and has a wide application prospect.

The invention discloses an application of a compound fresh bamboo juice in a guinea pig asthma model, and relates to the field of medicines, a Hartley albino guinea pig is adopted to construct an OVA induced asthma model, and the model is verified to be successfully constructed through evaluation indexes; evaluating the efficacy of the successfully constructed guinea pig asthma model by using different doses of compound fresh bamboo juice, and evaluating the efficacy of the guinea pig asthma model by scoring guinea pig capsaicin stimulation cough inducing times, alveolar lavage fluid leukocyte number, inflammatory factor content, lung tissue hydroxyproline content and behavioral signs. And evaluating the treatment effect of the compound fresh bamboo juice through Western blot detection, lung histopathology and immunofluorescence staining indexes. In a guinea pig asthma model, high-dose and medium-dose groups of the compound fresh bamboo juice can be used for remarkably reducing the number of cough, reducing the number of white blood cells in alveolar lavage fluid and the level of inflammatory factors and inhibiting pulmonary fibrosis, and a good treatment effect is shown. The results provide powerful support for potential application of the compound fresh bamboo juice in asthma treatment.

The utility model relates to the technical field of animal experiments, and discloses a rat asthma model test box which comprises a test box body and an atomizer arranged outside the test box body, and the output end of the atomizer is connected with a first test cavity and a second test cavity which are formed in the test box body through a connecting assembly. Box doors are installed at the opening ends of the first test cavity and the second test cavity, and a vibration assembly is installed in the second test cavity. A first test cavity and a second test cavity are formed in the test box, a vibration assembly vibration plate is arranged in the second test cavity, and two rats can be put into the first test cavity and the second test cavity respectively, so that one of the rats can be tested in the first test cavity in a normal respiratory rate state; and through cooperation of the vibration assembly and the vibration plate, another rat can be tested in the second test cavity in a state of relatively high respiratory rate, so that the rats in two different states can be observed and compared.

The invention belongs to the technical field of biomedicine, and discloses an antibody for evaluating the curative effect of infantile pneumonia asthma and application of the antibody. The heavy chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 2-4, the light chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 6-8, the dissociation constant of the monoclonal antibody and an IL-5R antigen reaches 2.435 * 10 <-1 > / L, and the affinity is high. The antibody can accurately evaluate the curative effect of infantile pneumonia and asthma by detecting the lung function, the ratio of eosinophilic granulocytes in bronchoalveolar lavage fluid and lung tissue inflammation, can also significantly improve airway obstruction and inflammation of asthma model mice, has an effect superior to that of dexamethasone, solves the problems that existing curative effect evaluation is lack of specific tools and has large side effects of therapeutic drugs, and has good clinical application prospects. And a new scheme is provided for curative effect evaluation and adjuvant therapy of infantile pneumonia asthma.

The invention discloses a budesonide-loaded ginseng vesicle delivery system and a construction method and application thereof, and belongs to the technical field of plant-derived nano-drug delivery systems. According to the delivery system, nano-vesicles from ginseng are taken as carriers, and budesonide is entrapped to form a BUD-coated GDNPs compound. The delivery system can synergistically enhance the anti-inflammatory effect of budesonide, significantly alleviate airway inflammation of asthma model animals, reduce side effects such as blood glucose disorder and the like caused by high-dose budesonide, and has excellent biological safety. The delivery system provided by the invention can be used for clinical treatment of asthma, is especially suitable for patients who need to use glucocorticoid for a long time, solves the technical problems of low bioavailability and obvious side effects of traditional budesonide, and has important clinical application value and industrialization prospect.

This invention discloses the application of Dongwan Zhike Granules in the preparation of drugs for treating cough-variant asthma, belonging to the field of traditional Chinese medicine technology. This invention induces a rat model of cough-variant asthma using an ovalbumin-aluminum hydroxide suspension, and then verifies the ameliorative effect of Dongwan Zhike Granules on this rat asthma model. Experiments demonstrate that Dongwan Zhike Granules, at low, medium, and high doses, have a certain ameliorative effect on the ovalbumin-aluminum hydroxide suspension-induced cough-variant asthma rat model. This invention provides a new application for Dongwan Zhike Granules and also provides important evidence for its application in the prevention and treatment of cough-variant asthma.

This invention provides a traditional Chinese medicine composition for treating or improving asthma, relating to the field of traditional Chinese medicine pharmaceutical technology. The composition comprises the following raw materials: Inula japonica, Bambusa textilis, Lysimachia christinae, Rutaecarpa, Ligusticum striatum, Pyrrosia lingua, Chaenomeles speciosa, Dioscorea hypoglauca, Atractylodes lancea, walnut kernel, maltose, Citronella arvense, and Glycyrrhiza uralensis. In this invention, each ingredient in the composition fulfills its specific function, addressing both the symptoms of asthma (phlegm and qi stagnation, and upward flow of lung qi) and the underlying causes (spleen strengthening, kidney tonification, and liver soothing). This achieves the combined effects of dispelling wind and clearing the lungs, resolving phlegm and descending rebellious qi, strengthening the spleen and resolving dampness, warming the kidneys and promoting qi circulation, and regulating liver qi. It treats both the symptoms and the root cause. This invention's composition effectively inhibits airway inflammation in asthma model mice, improves clinical symptoms, and demonstrates significant therapeutic effects. The composition exhibits a high overall effective rate in treating asthma, with particular advantages in alleviating clinical symptoms and improving lung function in asthma patients.

Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.

The invention belongs to the technical field of biological medicines, and relates to application of an interleukin 33 antibody in preparation of a medicine for relieving asthma aggravation, in particular to application of the interleukin 33 antibody in preparation of a medicine for relieving asthma aggravation induced by ozone exposure. According to the application disclosed by the invention, comprehensive research experiments are adopted, the intervention treatment of the IL-33 antibody is implemented by constructing an asthma model and utilizing an ozone-induced asthma exacerbation model, and the pathophysiological action of the IL-33 antibody in relieving ozone-induced asthma exacerbation is comprehensively disclosed. Experimental results show that the IL-33 antibody can relieve the conditions of asthma mouse lung dysfunction, lung tissue inflammatory cell infiltration and immune cell imbalance in lung tissue caused by ozone exposure. The invention provides a new perspective for the treatment of asthma, and provides a scientific basis and practical value for developing a novel and effective asthma prevention and treatment strategy. The traditional Chinese medicine composition is expected to improve the living quality of asthma patients and reduce health risks caused by environmental pollutants, and has important clinical significance and social value.

The invention discloses a lipid nanoparticle freeze-drying protective agent composition containing a mucus dissolving agent, a lipid nanoparticle preparation and application, and belongs to the technical field of biological medicine, and the freeze-drying protective agent composition comprises saccharides and the mucus dissolving agent. According to the invention, the saccharide and the mucus dissolving agent are combined to form a freeze-drying protective agent composition system for the first time. Through the synergistic effect of the carbohydrates and the mucus dissolving agent, the lipid nanoparticles can be stably stored at room temperature after being freeze-dried, a cold chain is not needed, the storage and transportation cost is remarkably reduced, and the clinical application convenience of the preparation is improved. In an in-vitro mucus model and an in-vivo mouse asthma model, it is proved that the medicine delivery efficiency of the lung can be effectively improved, and the treatment effect is enhanced.

The embodiment of the invention discloses a drought stress method for Artemisia impatiens and application. The method comprises the following steps: selecting seeds of Artemisia impatiens with full grains and uniform size, disinfecting, sowing in a culture dish, placing in a culture box, and transferring germs into a plastic basin for sunlight greenhouse culture after germination; the seedlings are subjected to drought stress treatment under the conditions that the concentration of PEG-6000 ranges from 5% to 30%, and the time ranges from 2 d to 6 d. According to the method, Artemisia impatiens is selected as a research object, two drought stress conditions of soil water content and PEG-6000 solution are set, and the influence of drought stress on physiological and biochemical characteristics of Artemisia impatiens seedlings and the content of eriodictyol-7-methyl ether and isosakuranetin with anti-inflammatory and asthma-relieving activities is discussed. Furthermore, TGF-beta1 is used for inducing mouse airway smooth muscle cells to construct an asthma model, and it is verified that the artemisia differentiata can effectively improve the asthma relieving activity after being subjected to drought stress. The method provides a theoretical basis for high-quality and high-efficiency cultivation of Artemisia impatiens.

This invention provides the use of a trisaccharide compound with a core structure of Glc(1→4)IdoA(1→4)GlcNS in the preparation of a drug for treating or preventing asthma. This compound can reduce lung inflammation in asthma model mice, reduce mucus production in the trachea, and effectively improve ventilation.

The invention discloses a preparation method and application of a traditional Chinese medicine spray for treating asthma, and belongs to the technical field of traditional Chinese medicine preparations. The stability problem of the traditional Chinese medicine spray is systematically solved through the synergistic effect of alcohol precipitation impurity removal, volatile oil clathration, pH regulation and control and the ternary stabilizer. Pharmacodynamic studies show that the spray can remarkably reduce the inflammatory factor level of asthma model mice and prolong the incubation period of asthma inducing of guinea pigs, has the effect better than that of oral granules, takes effect quickly and is suitable for quick relief in the acute attack period of asthma.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of asthma. The TCM composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that the TCM composition provided by this invention can effectively improve airway hyperresponsiveness, reduce lung resistance, and enhance dynamic lung compliance in asthma model animals. Simultaneously, it can significantly reduce the content of pro-inflammatory factors IL-4 and IL-13 in the bronchoalveolar lavage fluid of asthma models, alleviate airway inflammation, and relieve asthma pathological symptoms. It can stably exert its effect in preventing and treating asthma, and its efficacy is stable and its safety is good. It can be further developed into a drug for the prevention and treatment of asthma and has good clinical application prospects.